Mitogen-activated protein kinase inhibits 1,25-dihydroxyvitamin D3- dependent signal transduction by phosphorylating human retinoid X receptor α

Journal of Clinical Investigation

Volumn 103, Issue 12, 1999, Pages 1729-1735

  Solomon, Cynthia ^a   White, John H ^a,b   Kremer, Richard ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; MITOGEN ACTIVATED PROTEIN KINASE; RETINOID X RECEPTOR;

ARTICLE; CALCIUM HOMEOSTASIS; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

EID: 0032695358     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI6871     Document Type: Article

References (33)

1. McClay, E.F., Albright, K.D., Jones, J.A., Christen, R.D., and Howell, S.B. 1994. Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines. Br. J. Cancer. 70:449-452.
2. Zachos, G., and Spandidos, G.A. 1997. Expression of rat proto-oncogenes: regulation and implications in the development of human tumors. Crit. Rev. Oncol. Hematol. 26:65-75.
3. Davis, R.J. 1993. The mirogen-activated protein kinase signal transduction pathway. J. Biol. Chem. 268:14553-14556.
4. Weigel, N.L. 1994. Receptor phosphorylation in molecular biology intelligence unit. In Mechanism of steroid hormone regulation ofgene transcription. M-J. Tsai, editor. R.G. Landes Co. Austin, Texas. 93-110.
5. Haussler, M.R., et al. 1998. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J. Bone Miner. Res. 13:325-349.
6. 3 prolongs survival time of leukemic mice. Proc. Natl. Acad. Sci. USA. 87:3929-3932.
7. Buras, R.R., et al. 1994. Vitamin D receptors in breast cancer cells. Breast Cancer Res. Treat. 31:191-202.
8. 3 on endometrial carcinoma cell lines. J. Obstet. Gynaecol. Res. 22:529-539.
9. 3 on head and neck squamous cell carcinoma cell lines. Eur. Arch. Otorhinolaryngol. 253:341-344.
10. 3 and all-trans retinoic acid inhibit the growth of a lung cancer cell line. Anticancer Res. 16:2653-2659.
11. 3 in the human prostatic carcinoma cell line ALVA-31. J. Steroid Biochem. Mol. Biol. 58:277-288.
12. 3 receptor, retinoic acid receptors, and retinoid X receptors in U-937 cells. Cell Growth Differ. 7:1239-1249.
13. 3 in a keratinocyte model of rumor progression. J. Biol. Chem. 267:12162-12167.
14. Zugmaier, G., et al. 1996. Growth inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells. Br. J. Cancer. 73:1341-1346.
15. 3-resistant MCF-7 cell line. Endocrinology. 137:400-409.
16. Durst, M., Gallahan, D., Jay, G., and Rhim, J.S. 1989. Glucocorticoid-enhanced neoplastic transformation of human keratinocytes by human papilloma virus type 16 and an activated ras oncogene. Virology. 173:767-771.
17. Solomon, C., Sebag, M., White, J.H., Rhim, J., and Kremer, R. 1998. Disruption of vitamin D receptor-retinoid X receptor heterodimer formation following ras transformation of human keratinocytes. J. Biol. Chem. 273:17573-17578.
18. Mangelsdorf, D.J., and Evans, R.M. 1995. The RXR heterodimers and orphan receptors. Cell. 83:841-850.
19. Durst, M., Dzarlieva-Petrusevska, R.T., Boukamp, P., Fusenig, N.E., and Gissman, L. 1987. Molecular and cytogenetic analysis of immortalized human primary keratinocytes obtained after transfection with human papilloma virus type 16 DNA. Oncogene. 1:251-256.
20. 3. J. Biol. Chem. 269:2971-2981.
21. Dudley, D.T., Pang, L., Decker, S.J., Bridges, A.J., and Saltiel, A.R. 1995. A synthetic inhibitor of the mitogen activated protein kinase cascade. Proc. Natl. Acad. Sci. USA. 92:7686-7689.
22. Banville, D., and Boie, V. 1990. Retroviral long terminal repeat is the promoter of the gene encoding rhe tumor-associated calcium-binding protein oncomodulin in the rat. J. Mol. Biol. 207:481.
23. Koszewski, N., Reinhardt, T., and Horst, R. 1996. Vitamin D receptor interactions with the murine osteopontin response element. J. Steroid Biochem. 59:377-388.
24. Ho, S.N., Hunt, H.D., Horton, R.M., Pullen, J.K., and Pease, L.R. 1989. Site directed mutagenesis by overlap extension using the polymerase chain reaction. Gene. 77:51-59.
25. Henderson, J., Sebag, M., Rhim, J., Goltzman, D., and Kremer, R. 1991. Dysregulation of parathyroid hormone-like peptide expression and secretion in a keratinocyte model of tumor progression. Cancer Res 51:6521-6528.
26. Kaiser, S.M., Sebag, M., Rhim, J.S., Kremer, R., and Goltzman, D. 1994. Antisense-mediated inhibition of parathyroid hormone-related peptide production in a keratinocyte cell line impedes differentiation. Mol. Endocrinol. 8:139-147.
27. Niles, R.M. 1995. Use of vitamins A and D in chemoprevention and therapy of cancer: control of nuclear receptor expression and function. Adv. Exp. Med. Biol. 375:1-15.
28. 2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell. 83:813-819.
29. Sarraf, P., et al. 1998. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat. Med. 4:1046-1052.
30. Westin, S., et al. 1998. Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators. Nature. 395:199-202.
31. Henttu, P.M., Kalkoven, E., and Parker, M.G. 1997. AF-2 activity and recruitment of steroid receptor coactivator 1 to the estrogen receptor depend on a lysine residue conserved in nuclear receptors. Mol. Cell. Biol. 17:1832-1839.
32. Meyer, M.E., et al. 1989. Steroid hormone receptors compete for factors that mediate their enhancer function. Cell. 57:433-442.
33. Nolte, R.T., et al. 1998. Ligand binding and coactivator assembly of the peroxisome proliferator-activated receptor-gamma. Nature. 395:137-143.